Glomerular mRNA expression of prothrombotic and antithrombotic factors in renal transplants with thrombotic microangiopathy

Transplantation. 2013 May 27;95(10):1242-8. doi: 10.1097/TP.0b013e318291a298.

Abstract

Background: Thrombotic microangiopathy (TMA) in renal transplants (rTx-TMA) is a serious complication and is usually either recurrent TMA (RecTMA) due to humoral rejection (HR-TMA) or due to calcineurin inhibitor toxicity (CNI-TMA). Although the triggers are known, our knowledge about the thrombogenic transcriptome changes in the microvessels is rudimentary.

Methods: We examined the expression of several prothrombotic and antithrombotic genes in 25 biopsies with rTx-TMA (6 RecTMA, 9 HR-TMA, and 10 CNI-TMA) and 8 controls. RNA from microdissected glomeruli of paraffin-embedded tissue was isolated and mRNA transcripts were quantified with real-time polymerase chain reaction after preamplification. Results were correlated with clinicopathologic parameters.

Results: Glomerular mRNA expression of KLF2, KLF4, and tPA was lower and that of PAI-1 was higher in rTx-TMA than in the controls. Glomerular mRNA expression of KLF2 and KLF4 correlated with that of tPA and inversely with that of PAI-1 in rTx-TMA. The mRNA expression of complement regulators CD46 and CD59 were higher in rTx-TMA than in the controls. Only in HR-TMA were glomerular ADAMTS13 and CD55 down-regulated.

Conclusions: The glomerular capillary bed seems to contribute to all subtypes of rTx-TMA by down-regulation of the endothelial transcription factors KLF2 and KLF4, indicating dedifferentiation with subsequent up-regulation of PAI-1 and down-regulation of tPA, resulting in inhibition of local fibrinolysis. Decreased glomerular expression of ADAMTS13 and CD55 could be an additional pathway toward microthrombosis exclusively in HR-TMA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAM Proteins / genetics
  • ADAMTS13 Protein
  • Adult
  • Aged
  • Calcineurin Inhibitors
  • Female
  • Humans
  • Kidney Glomerulus / metabolism*
  • Kidney Transplantation / adverse effects*
  • Kruppel-Like Factor 4
  • Kruppel-Like Transcription Factors / analysis
  • Kruppel-Like Transcription Factors / genetics
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / genetics
  • RNA, Messenger / analysis*
  • Thrombotic Microangiopathies / metabolism*
  • Tissue Plasminogen Activator / analysis
  • Tissue Plasminogen Activator / genetics

Substances

  • Calcineurin Inhibitors
  • KLF2 protein, human
  • KLF4 protein, human
  • Kruppel-Like Factor 4
  • Kruppel-Like Transcription Factors
  • Plasminogen Activator Inhibitor 1
  • RNA, Messenger
  • Tissue Plasminogen Activator
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human